متابعة
Marzia Del Re, PharmD, PhD
Marzia Del Re, PharmD, PhD
Senior Researcher @ Unit of Clinical Pharmacology and Pharmacogenetics, University of Pisa
بريد إلكتروني تم التحقق منه على unipi.it
عنوان
عدد مرات الاقتباسات
عدد مرات الاقتباسات
السنة
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …‏
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...‏
JAMA oncology 5 (3), 343-350, 2019‏
3552019
The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients‏
M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi, C Orlandini, M Miccoli, ...‏
European urology 71 (4), 680-687, 2017‏
2662017
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC‏
M Del Re, R Marconcini, G Pasquini, E Rofi, C Vivaldi, F Bloise, ...‏
BRITISH JOURNAL OF CANCER, 1-5, 2018‏
2282018
Clinical pharmacology of intravitreal anti-VEGF drugs‏
S Fogli, M Del Re, E Rofi, C Posarelli, M Figus, R Danesi‏
Eye 32 (6), 1010-1020, 2018‏
1882018
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis‏
S Terrazzino, S Cargnin, M Del Re, R Danesi, PL Canonico, ...‏
Pharmacogenomics 14 (11), 1255-1272, 2013‏
1702013
Contribution of KRAS mutations and c. 2369C> T (p. T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA‏
M Del Re, M Tiseo, P Bordi, A D'Incecco, A Camerini, I Petrini, M Lucchesi, ...‏
952016
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy‏
R Minari, P Bordi, M Del Re, F Facchinetti, F Mazzoni, F Barbieri, ...‏
Lung Cancer 115, 21-27, 2018‏
922018
EGFR signaling pathway as therapeutic target in human cancers‏
E Levantini, G Maroni, M Del Re, DG Tenen‏
Seminars in Cancer Biology 85, 253-275, 2022‏
912022
Updates on liquid biopsy: Current trends and future perspectives for clinical application in solid tumors‏
P Pinzani, V D’Argenio, M Del Re, C Pellegrini, F Cucchiara, F Salvianti, ...‏
Clinical Chemistry and Laboratory Medicine (CCLM) 59 (7), 1181-1200, 2021‏
892021
Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment‏
E Arrigoni, M Del Re, S Galimberti, G Restante, E Rofi, S Crucitta, ...‏
Stem cells translational medicine 7 (3), 305-314, 2018‏
882018
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.‏
M Del Re, C Vivaldi, E Rofi, E Vasile, M Miccoli, C Caparello, P d'Arienzo, ...‏
Sci Rep. 7 (1), 7931, 2017‏
802017
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy‏
M Del Re, S Crucitta, G Gianfilippo, A Passaro, I Petrini, G Restante, ...‏
International journal of molecular sciences 20 (16), 3951, 2019‏
792019
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients‏
M Del Re, I Bertolini, S Crucitta, L Fontanelli, E Rofi, C De Angelis, ...‏
Breast Cancer Research and Treatment 178, 57-62, 2019‏
772019
The molecular profiling of solid tumors by liquid biopsy: A position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies‏
A Russo, L Incorvaia, M Del Re, U Malapelle, E Capoluongo, V Gristina, ...‏
ESMO open 6 (3), 100164, 2021‏
762021
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer‏
P Bordi, M Del Re, R Danesi, M Tiseo‏
Translational lung cancer research 4 (5), 584, 2015‏
762015
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity‏
A Di Paolo, G Bocci, M Polillo, M Del Re, T Di Desidero, M Lastella, ...‏
Current Drug Metabolism 12 (10), 932-943, 2011‏
752011
The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide‏
M Del Re, S Fogli, L Derosa, F Massari, P De Souza, S Crucitta, ...‏
Cancer treatment reviews 55, 71-82, 2017‏
692017
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema‏
S Fogli, S Mogavero, CG Egan, M Del Re, R Danesi‏
Pharmacological research 103, 149-157, 2016‏
682016
Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer‏
I Casanova-Salas, A Athie, PC Boutros, M Del Re, DT Miyamoto, ...‏
European urology 79 (6), 762-771, 2021‏
602021
Detection of ALK and KRAS mutations in circulating tumor DNA of patients with advanced ALK-positive NSCLC with disease progression during crizotinib treatment‏
P Bordi, M Tiseo, E Rofi, I Petrini, G Restante, R Danesi, M Del Re‏
Clinical lung cancer 18 (6), 692-697, 2017‏
582017
يتعذر على النظام إجراء العملية في الوقت الحالي. عاود المحاولة لاحقًا.
مقالات 1–20